Merck Targets Upped -- To $59; And $62 -- At Two Wall Street Shops: Suggests Fully Valued, Here

Tonight, two firms have updated their outlooks -- on Merck.

Both are only incrememntal bumps. Both suggest essentially neutral ratings, and both thus suggest that Merck is pretty fully valued at $58, or so. Links here, and here.

. . . .Merck's stock had its “neutral” rating reaffirmed by Credit Suisse in a research note issued on Thursday. They currently have a $59.00 price target on the stock, up from their previous price target of $56.00. Credit Suisse’s price target suggests a potential upside of 1.58% from the company’s current price. . . .

Analysts at BMO Capital Markets raised their price objective on shares of Merck & Co. (NYSE:MRK) from $60.00 to $62.00 in a research report issued to clients and investors on Thursday [and continued their "market perform" rating]. . . .

So it goes.